On 12 January, the EMA implemented the revamped EU HTA regulation for the assessment of cancer therapies and cell and gene therapies. Credit: Vepar5 via
Neumora’s share price plummeted after the company shared news on a Phase III trial failure for its lead candidate. Credit: Ground Picture via Shutterstock Neumora
Credit: Ulrich Baumgarten via Getty Images. Dr Jonathan Weber shared insights on the HIV prophylactic landscape, citing the transformative impact of PrEP therapies. Research activity
At the Outsourcing in Clinical Trials Conference in New England, experts shared insights on how the US clinical trial and pharmaceutical space could keep up
As biosimilars enter the psoriasis market, key opinion leaders anticipate a shift in patient preference from IL-23 therapies to IL-17 therapies due to pricing and
In an exclusive interview with Pharmaceutical Technology, Dr Kenneth Getz attributed the wave of pharma layoffs to patent cliffs and uncertainty due to the upcoming
At the Outsourcing in Clinical Trials Conference in New England, the CBP warned attendees of the common legal pitfalls researchers make in transporting material for
At the Outsourcing in Clinical Trials Conference in New England, the associate director of a UAE contract research organisations shared the opportunities for clinical research
At the Outsourcing in Clinical Trials conference in New England, Andarix Pharmaceuticals’ CEO shared the uses of social media for improved rare disease trial patient
As AI makes clinical operations more streamlined, companies will have to adapt their workforces to the new technology, say experts at the Outsourcing in Clinical